These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Implementing the new oral anticoagulants into the hospital formulary. Palladino M; Thomson L; Swift B; Merli GJ Am J Hematol; 2012 May; 87 Suppl 1():S127-32. PubMed ID: 22495943 [TBL] [Abstract][Full Text] [Related]
3. Role of Direct Oral Anticoagulants in the Management of Anticoagulation. Thakkar RN; Rathbun SW; Wright SM South Med J; 2017 Apr; 110(4):293-299. PubMed ID: 28376529 [TBL] [Abstract][Full Text] [Related]
4. The new oral anticoagulants: a challenge for hospital formularies. Merli GJ Hosp Pract (1995); 2012 Aug; 40(3):126-8. PubMed ID: 23086101 [TBL] [Abstract][Full Text] [Related]
5. Recent developments in the use of oral anticoagulants. Lassen MR Expert Opin Pharmacother; 2009 Aug; 10(11):1769-81. PubMed ID: 19548861 [TBL] [Abstract][Full Text] [Related]
6. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. Ma TK; Yan BP; Lam YY Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530 [TBL] [Abstract][Full Text] [Related]
7. New anticoagulants for the prevention of thromboembolism. Lepic K; Crowther M Curr Pharm Des; 2010; 16(31):3472-4. PubMed ID: 20858184 [TBL] [Abstract][Full Text] [Related]
8. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Becattini C; Vedovati MC; Agnelli G Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937 [TBL] [Abstract][Full Text] [Related]
10. Implications of new anticoagulants in primary practice. Perez A; Eraso LH; Merli GJ Int J Clin Pract; 2013 Feb; 67(2):139-56. PubMed ID: 23305476 [TBL] [Abstract][Full Text] [Related]
11. The role of apixaban for venous and arterial thromboembolic disease. Prom R; Spinler SA Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450 [TBL] [Abstract][Full Text] [Related]
12. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. Quinlan DJ; Eriksson BI Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905 [TBL] [Abstract][Full Text] [Related]
13. Novel oral anticoagulants: a review of new agents. Wanat MA Postgrad Med; 2013 Jul; 125(4):103-14. PubMed ID: 23933899 [TBL] [Abstract][Full Text] [Related]
14. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW; Barillari G J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983 [TBL] [Abstract][Full Text] [Related]
15. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Stangier J; Clemens A Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042 [TBL] [Abstract][Full Text] [Related]
16. [Prophylaxis of venous thromboembolism in orthopedic surgery. Role of the new anticoagulants]. Guijarro Merino R; Villalobos Sánchez A Med Clin (Barc); 2012 Oct; 139 Suppl 2():13-8. PubMed ID: 23498067 [TBL] [Abstract][Full Text] [Related]
17. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
18. Target-specific oral anticoagulants: practice issues for the clinician. Plitt A; Giugliano RP Hosp Pract (1995); 2014 Aug; 42(3):48-61. PubMed ID: 25255406 [TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban: an oral factor Xa inhibitor. Thomas TF; Ganetsky V; Spinler SA Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267 [TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]